1. Concurrent Hearing and Genetic Screening of 180,469 Neonates with Follow-up in Beijing, China
- Author
-
Liping Zhao, Dong Yang Kang, De Min Han, Hai Hong Liu, Hong Jiang, Chun Yan Qu, Hai Meng Huang, Xin Ni, Jin Sheng Hao, Zhen Zhou, Jie Zhang, Jia Ke, Wei Zhang, Wan Li Xing, Ping Liu, Ru Zhen Gao, Xue Zhong Liu, Wan Xia Zhang, Hong Li Lu, Sha Sha Huang, Yongyi Yuan, Shu Yan Xi, Yi Zhou, Jie Qiao, Fu Rong Ma, Mo Long, Li Hui Huang, Xin Zhang, Ying Nan Jin, Guojian Wang, Luo Zhang, Bin Rong Ma, Yong Li Guo, Jing Cheng, Ying Pan, Fan Lyu, Wei Liang, Xiao Wei Chen, Liang Chang, Cynthia C. Morton, Hong Duan, Xiao Hua Cheng, Pu Dai, Xue Gao, Di Jiang, and Ke Zhang
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Population ,education.educational_degree ,Otoacoustic emission ,Compound heterozygosity ,Habilitation ,Article ,Ototoxicity ,Genetics ,otorhinolaryngologic diseases ,Medicine ,Humans ,Genetic Predisposition to Disease ,Genetic Testing ,education ,Hearing Loss ,Genetics (clinical) ,Genetic testing ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Infant, Newborn ,Heterozygote advantage ,medicine.disease ,Beijing ,Female ,Dried Blood Spot Testing ,business ,Cohort study - Abstract
Concurrent hearing and genetic screening of newborns is expected to play important roles not only in early detection and diagnosis of congenital deafness, which triggers intervention, but also in predicting late-onset and progressive hearing loss and identifying individuals who are at risk of drug-induced HL. Concurrent hearing and genetic screening in the whole newborn population in Beijing was launched in January 2012. This study included 180,469 infants born in Beijing between April 2013 and March 2014, with last follow-up on February 24, 2018. Hearing screening was performed using transiently evoked otoacoustic emission (TEOAE) and automated auditory brainstem response (AABR). For genetic testing, dried blood spots were collected and nine variants in four genes, GJB2, SLC26A4, mtDNA 12S rRNA, and GJB3, were screened using a DNA microarray platform. Of the 180,469 infants, 1,915 (1.061%) were referred bilaterally or unilaterally for hearing screening; 8,136 (4.508%) were positive for genetic screening (heterozygote, homozygote, or compound heterozygote and mtDNA homoplasmy or heteroplasmy), among whom 7,896 (4.375%) passed hearing screening. Forty (0.022%) infants carried two variants in GJB2 or SLC26A4 (homozygote or compound heterozygote) and 10 of those infants passed newborn hearing screening. In total, 409 (0.227%) infants carried the mtDNA 12S rRNA variant (m.1555A>G or m.1494C>T), and 405 of them passed newborn hearing screening. In this cohort study, 25% of infants with pathogenic combinations of GJB2 or SLC26A4 variants and 99% of infants with an m.1555A>G or m.1494C>T variant passed routine newborn hearing screening, indicating that concurrent screening provides a more comprehensive approach for management of congenital deafness and prevention of ototoxicity.
- Published
- 2019
- Full Text
- View/download PDF